TORC1 inhibition enhances immune function and reduces infections in the elderly

#1

I must have missed it, but I didn’t see any thread on this 2018 Mannick paper (PROTECT trial), which was a followup to the 2014 study. @RapAdmin , feel free to give this paper your full treatment if you want. AI summary below

Precision TORC1 Inhibition Reverses Immunosenescence in Elderly Humans

Aging is characterized by immunosenescence, a progressive decline in immune function that renders the elderly highly susceptible to infections, particularly respiratory tract infections which are a leading cause of global mortality. Central to this decline is the mechanistic target of rapamycin (mTOR) pathway. While inhibiting the mTOR complex 1 (TORC1) has consistently extended lifespan and improved immune markers in animal models, translating these findings to humans has been hampered by the side effects associated with broader mTOR inhibition, such as TORC2 suppression which can lead to metabolic dysfunction.

This Phase 2a randomized, placebo-controlled trial investigated a novel approach: using ultra-low doses of a rapalog (RAD001/Everolimus) and a catalytic site mTOR inhibitor (BEZ235/Dactolisib) to selectively target TORC1. The study enrolled 264 elderly subjects who were treated for six weeks and followed for one year. The primary objective was to determine if this pharmacological “dialing down” of TORC1 could safely boost immune response to the influenza vaccine and reduce real-world infection rates.

The results demonstrated that the combination of 0.1 mg RAD001 and 10 mg BEZ235 significantly enhanced the humoral response to the influenza vaccine across all three tested strains. More importantly, the treatment group experienced a 38% reduction in the annualized rate of self-reported infections compared to the placebo group (P=0.001). This benefit was particularly pronounced in respiratory tract infections. Mechanistically, the researchers observed a significant up-regulation of antiviral gene expression, specifically type 1 interferon-induced genes, which likely fortified the innate immune response against viral pathogens.

Critically, these low doses avoided the adverse metabolic effects of TORC2 inhibition, such as hyperglycemia or hypercholesterolemia. The findings strongly suggest that intermittent, low-dose TORC1 inhibition is a viable strategy to enhance “healthspan” by rejuvenating the aging immune system, providing a rare successful clinical translation of a core longevity-science concept.

Actionable Insights

  • Dose-Response Sensitivity: Low doses of mTOR inhibitors (3- to 100-fold lower than oncology or transplant doses) are sufficient to enhance immune function without causing immunosuppression or metabolic toxicity.

  • Combination Synergy: Combining a rapalog (allosteric) with a catalytic inhibitor provides a more complete suppression of TORC1 substrates (like 4EBP1) than either drug alone, leading to superior clinical outcomes in vaccine response.

  • Persistence of Benefit: A short 6-week course of treatment resulted in a reduction in infections that persisted for a full year, suggesting a lasting “reboot” of immune pathways rather than a requirement for chronic administration.

  • Antiviral Priming: The primary mechanism of infection reduction appears to be the up-regulation of interferon-stimulated genes, which enhances the body’s innate ability to fight multiple viral serotypes simultaneously.

  • Safety Profile: The most common side effect was mild diarrhea; metabolic markers like glucose and cholesterol remained stable, confirming the selectivity of the low-dose regimen for TORC1 over TORC2.

Context

The study is a seminal piece of research in geroscience, shifting the focus from simply extending lifespan in animals to enhancing “healthspan” and immune function in humans.

Study Link

The 2018 study, published in Science Translational Medicine, is titled: TORC1 inhibition enhances immune function and reduces infections in the elderly (Mannick et al., 2018).

Background and Relation to the 2014 Study

The 2018 study (PROTECT) was a Phase 2a clinical trial designed to build upon the findings of the 2014 Phase 1 trial.

  • The 2014 Study (The “Prior”): mTOR inhibition improves immune function in the elderly. This study established that low-dose mTOR inhibition (using RAD001/Everolimus) could “rejuvenate” the immune system of elderly adults, specifically by increasing the response to the influenza vaccine and decreasing the expression of PD-1 on T cells (a marker of exhaustion).
  • The 2018 Study (The “Update”): While the 2014 study looked at a single drug and vaccine response (a proxy for immune health), the 2018 PROTECT study expanded the scope to see if these drugs could reduce the actual incidence of Respiratory Tract Infections (RTIs) over a full year.
  • The Shift in Hypothesis: The 2018 study shifted focus specifically to TORC1 (Target of Rapamycin Complex 1). The researchers hypothesized that selective inhibition of TORC1—without significantly inhibiting TORC2—would provide the immune benefits of rapamycin without the negative metabolic side effects (like insulin resistance) typically associated with high-dose or chronic mTOR inhibition. [Confidence: High]

Study Design Specifications

The 2018 trial was a randomized, double-blind, placebo-controlled Phase 2a study.

  • Participants: 264 elderly subjects (age 65+).
  • Treatment Duration: Subjects were treated for 6 weeks .
  • Follow-up: Subjects were monitored for one year after the treatment period ended.
  • Primary Goal: To assess the safety and efficacy of low-dose mTOR inhibitors in reducing self-reported and laboratory-confirmed RTIs.
  • Key Biological Markers Assessed:
    • Antiviral gene expression (specifically Type I Interferon-induced genes).
    • Response to influenza vaccination.

Key Findings by Drug Used

The study compared several low-dose regimens against a placebo. The results showed that the efficacy was highly dependent on the specific drug combination and dose.

Drug / Regimen Finding
RTB101 (BEZ235) A catalytic mTOR inhibitor. Used alone, it showed moderate improvements in antiviral gene expression but was most effective when combined.
Everolimus (RAD001) An allosteric mTOR inhibitor (a rapalog). Similar to the 2014 study, it showed immune-enhancing properties at very low doses.
The Combination (RTB101 + Everolimus) The most successful group. This combination at a specific low dose (10 mg RTB101 + 0.1 mg Everolimus) led to a 30.6% reduction in the annual rate of infections compared to placebo (P = 0.001). [Confidence: High]

Evidence Update (Bayesian Perspective)

  • Priors: Before these studies, the consensus was that mTOR inhibitors were solely “immunosuppressants” (used to prevent organ transplant rejection).
  • Update: These results significantly updated the scientific prior: at low/intermittent doses , mTOR inhibitors act as immunomodulators that enhance antiviral defense rather than suppressing it.
  • Alternative Hypothesis: It is possible that the reduction in RTIs was due to improved epithelial barrier function in the lungs rather than systemic immune “rejuvenation,” though the increase in interferon-stimulated genes strongly suggests an immune mechanism. [Est. Probability: ~75% for immune mechanism].

Crucial Distinctions

  1. Mechanism vs. Outcome: While the study showed a clear reduction in infection rates (Human Outcome), the specific reason why (Mechanism) is still debated. The study highlights an increase in interferon-induced antiviral genes , which likely explains the resistance to viruses like rhinovirus and coronavirus.
  2. Safety: In contrast to high-dose rapamycin, these low doses were well-tolerated, with side effect profiles similar to placebo.

Note: It is important to remember that subsequent Phase 3 trials (conducted later by resTORbio) failed to meet their primary endpoints in a broader population, which suggests that the benefits of RTB101 may be specific to certain age groups (e.g., those 85+) or specific types of viral threats. [Confidence: High]

2 Likes
#2

The most successful group used a combination of allosteric inhibitor (rapamycin, etc), and a catalytic one. It is speculated that the combination was more effective because it blocked all 3 downstream nodes of mtor: S6K, S6, and 4EBP1. Maybe we can find compounds that block 4EBP1. Here is a list, according to AI

1. PI3K and AKT Inhibitors

The PI3K/AKT pathway is the primary “upstream” activator of mTORC1. When this pathway is active, it signals mTORC1 to phosphorylate 4E-BP1, releasing it from the translation machinery.

  • Examples: Alpelisib (PI3K inhibitor), Ipatasertib (AKT inhibitor).
  • Mechanism: By blocking the signal before it ever reaches mTOR, these drugs prevent the phosphorylation of 4E-BP1, keeping it in its active, inhibitory state (blocking protein synthesis).

2. Metformin (AMPK Activators)

Metformin is the most widely used indirect modulator of this pathway in the longevity space.

  • Mechanism: Metformin activates AMPK (the cell’s energy sensor). AMPK inhibits mTORC1 through two distinct routes:
    1. It phosphorylates and activates TSC2 (a natural mTOR inhibitor).
    2. It directly phosphorylates Raptor (a key component of mTORC1).
  • Result: This dual-pronged attack reduces mTORC1 activity, leading to less phosphorylation of 4E-BP1.

3. MAPK / ERK Pathway Inhibitors

The “growth” signals in a cell don’t just travel through the PI3K/mTOR highway; they also use the MAPK/ERK pathway.

  • Mechanism: ERK and RSK (kinases in this pathway) can independently phosphorylate 4E-BP1 at specific sites. This means even if you block mTOR, the cell might still translate proteins via the MAPK pathway.
  • Examples: Trametinib (MEK inhibitor), Selumetinib.
  • Impact: These are often used in combination with mTOR inhibitors in cancer research to ensure 4E-BP1 is “locked down” from all sides.

4. MNK Inhibitors

The MNK (MAPK-interacting kinase) enzymes are perhaps the most “downstream” indirect modulators.

  • Mechanism: MNKs primarily phosphorylate eIF4E (the protein that 4E-BP1 binds to). While they don’t bind 4E-BP1 directly, they control the same translation initiation complex (eIF4F).
  • Examples: Tomivosertib (eFT508).
  • Significance: By inhibiting MNKs, researchers hope to achieve similar effects to 4E-BP1 modulation but with much lower toxicity than hitting the “master switch” of mTOR.

Summary Table: Indirect 4E-BP1 Modulation

Intervention Primary Target Effect on 4E-BP1
Metformin AMPK (Activator) Indirectly decreases phosphorylation (inhibits translation).
Alpelisib PI3K (Inhibitor) Blocks upstream signal; decreases phosphorylation.
Trametinib MEK/ERK (Inhibitor) Blocks secondary phosphorylation route for 4E-BP1.
Sapanisertib mTOR (Catalytic) Directly prevents phosphorylation of all 4E-BP1 sites.

Why 4E-BP1 is the “Hard Part”

The reason many researchers are obsessed with 4E-BP1 is that Rapamycin (Sirolimus) is notoriously bad at modulating it. Rapamycin is excellent at blocking the S6K pathway, but 4E-BP1 is often resistant to “rapalogs.” This is why the 2018 Mannick study you mentioned was so significant—it used the catalytic inhibitor BEZ235 specifically because it could hit the 4E-BP1 “gate” much harder than Rapamycin alone.

2 Likes
#3

The inclusion of Trametinib above suggest that it’s probable that its efficacy is due to complete blockade of mtor via S6, S6K, and 4E-BP1 . See the thraead for this compound here:

1 Like
#4

It’s important to address this later development. Matt Kaeberlein (who was advising resTORbio at the time) wrote up a good paper that covers the unique situation in this clinical trial.

The Wrong Tool for the Job: Why the PROTECTOR1 Failure Does Not Refute the Biology of Aging

The geroscience hypothesis—the idea that targeting the shared molecular roots of aging can delay a multitude of chronic diseases—recently faced a public setback that, upon closer inspection, is less a failure of theory and more a failure of drug selection. The biopharmaceutical firm resTORbio terminated its Phase 3 PROTECTOR1 clinical trial after its lead candidate, RTB101, failed to reduce symptomatic respiratory illness in healthy older adults. While headlines may suggest a blow to longevity science, the technical reality is that the trial was never a true test of the geroscience hypothesis.

The primary issue lies in the pharmacological profile of RTB101 compared to rapamycin, the gold-standard geroprotector. While rapamycin is an allosteric inhibitor of mTOR Complex 1 (mTORC1) that consistently extends lifespan and healthspan across species, RTB101 is an ATP-competitive inhibitor targeting both mTORC1 and mTOR Complex 2 (mTORC2), alongside phosphoinositide-3-kinase (PI3K). Crucially, RTB101 lacks the preclinical evidence of lifespan extension or age-delaying effects that characterize true geroprotective compounds.

The failure of the Phase 3 trial may stem from shifting away from the successful parameters of earlier studies. Phase 2 trials showed promise when using either the rapalog everolimus (a specific mTORC1 inhibitor) or a combination of everolimus and RTB101. However, the Phase 3 trial utilized RTB101 alone and extended the treatment duration from 6 to 16 weeks. This shift likely diluted the specific mTORC1-mediated immune rejuvenation observed in previous preclinical and clinical models.

Despite this, the broader field remains robust. The trial confirmed the safety and feasibility of utilizing mTOR inhibitors in healthy elderly populations, showing no significant side effects. As the industry moves toward new, more selective mTORC1 inhibitors and continues testing off-patent rapalogs, the fundamental premise—that modulating the biology of aging can improve human health—remains statistically and biologically sound.

Actionable Insights

  • Differentiate mTOR Inhibitors: Do not conflate all “mTOR inhibitors.” Allosteric inhibitors like rapamycin and everolimus (RAD001) specifically target mTORC1 and have a proven track record of life extension in animal models. [Confidence: High]

  • Target mTORC1, Not mTORC2: The therapeutic window for longevity likely requires preserving mTORC2 function; drugs like RTB101 that hit both complexes may lack the “geroprotective” benefits seen with specific mTORC1 inhibition. [Confidence: Medium]

  • Focus on Rapalogs for Immunity: Preclinical and Phase 2 data strongly support the use of specific mTORC1 inhibitors to rejuvenate immune response and improve vaccine efficacy in the elderly. [Confidence: High]

  • Low-Dose Safety Profile: Short-term or intermittent use of low-dose mTOR inhibitors appears safe for healthy older adults, with minimal side effects reported in human trials and companion dog studies. [Confidence: High]

  • Topical Potential: For immediate application, topical rapamycin has shown promise in reversing human skin aging markers. [Confidence: Medium]

Context

  • Open Access Paper: RTB101 and immune function in the elderly: Interpreting an unsuccessful clinical trial
  • Institution: Department of Pathology, School of Medicine, University of Washington.
  • Country: USA.
  • Journal Name: Translational Medicine of Aging.
    Impact Evaluation -The impact score (CiteScore 2020) of this journal is 5.4, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.
1 Like